Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Indivior subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment

The FTSE 250-listed firm said the agency requested documents relating to the preparation of Suboxone Film, manufacturing records, and the potential to develop dependency on the treatment
Drug user
Indivior said it "intends to comply with the CDI’s subpoena and will cooperate in any related government inquiry”

Indivior PLC (LON:INDV) has revealed that its wholly-owned US subsidiary has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film.

In a statement, the FTSE 250-listed dugs group said the Californian agency, which is charged with overseeing insurance regulations, requested documents from its US unit relating to the preparation of the drug, manufacturing records, and the potential to develop dependency on the treatment.

READ: Indivior settles patent infringement litigation related to Suboxone drug

The firm, which was spun out from Reckitt Benckiser PLC (LON:RB.) in 2014 said: “Indivior intends to comply with the CDI’s subpoena and will cooperate in any related government inquiry.”

Earlier this month, Indivior reached an agreement with a group of drug companies to settle litigation over patent infringement of its Suboxone opioid addiction treatment.

The company said it settled with Par Pharmaceutical Inc., Par Pharmaceutical Companies Inc., Endo International PLC (referred to collectively as Par) and IntelGenx Technologies Corp.

View full INDV profile View Profile

Indivior Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use